No Data
Sinopharm's Q1 Profit Jumps
SINOPHARM released its quarterly performance, with a net income of 1.457 billion yuan, an increase of 2.59% year-on-year.
SINOPHARM (01099) released the financial information for the quarter ending March 31, 2025, with total operating revenue of 141.662 billion yuan, a year-on-year decrease of 3.81%; net income attributable to shareholders of the parent company was 1.457 billion yuan, a year-on-year increase of 2.59%; basic EPS was 0.47 yuan.
SINOPHARM (01099.HK): In the first quarter, the net income attributable to the parent company was 1.457 billion yuan, an increase of 2.6% year-on-year.
On April 28, Gelonghui reported that SINOPHARM (01099.HK) announced that for the three months ending March 31, 2025, it achieved total operating revenue of 141.662 billion yuan, a year-on-year decrease of 3.81%; net income attributable to the parent company's owners was 1.457 billion yuan, a year-on-year increase of 2.6%; EPS was 0.47 yuan.
SINOPHARM (01099.HK): It is recommended to appoint Chen Weiru as an independent non-executive Director.
On April 28, Gelonghui reported that SINOPHARM (01099.HK) announced that due to reaching the term of tenure for independent non-executive directors, Chen Fangruo will resign from the positions of independent non-executive director, member of the nomination committee, and member of the strategic and investment committee on April 25, 2025, effective from the date when the replacement is appointed at the company's shareholder meeting. On the same day, the Board of Directors resolved to recommend appointing Chen Weiru as an independent non-executive director.
Sinopharm Group 1Q Net CNY1.46B Vs. Net CNY1.42B >1099.HK
Sinopharm Group 1Q Rev CNY141.66B Vs. CNY147.27B >1099.HK
Cui Nyonya Kueh :
Musang Siguntang : ???